Viriom Inc., of San Diego, said it raised $4.7 million of equity and non-equity financing, including a three-year grant of 150 million rubles (US$2.35 million) from the Skolkovo Foundation, for the development of fixed-dose combinations and long-acting injection formulations of Elpida (elpivirine), its non-nucleoside reverse transcriptase inhibitor for HIV/AIDS.